City of Miami Purchases
AEDs for Police Vehicles Under Citywide PAD Program
PR Newswire
April 11th, 2005
IRVINE, Calif., April 11 /PRNewswire-FirstCall/
-- Cardiac Science, Inc.
(Nasdaq: DFIB), a leading manufacturer of public-access
defibrillators (AEDs),
today announced that the city of Miami purchased approximately
100 new fully-
automatic version Powerheart(R) G-3 AEDs as part of
its citywide Public Access
Defibrillation Program (PAD). The $200,000 order for
Miami's "Team for Life"
PAD project follows the City's initial order last
Fall for 42 Powerhearts that
were deployed in city buildings and parks. The latest
deployment of
Powerhearts are earmarked principally for use in city
police vehicles.
Miami's PAD project is an exclusive public-private
partnership between the
city and Cardiac Science. The goal of the project,
which is being coordinated
by the Miami Department of Fire-Rescue, is to save
lives and protect Miami
citizens and visitors by making AEDs more accessible
in a variety of settings
throughout the city. The program includes comprehensive
AED/CPR training and
AED program management services and a citywide public
awareness campaign on
the importance of defibrillation therapy and the use
of AEDs to treat victims
of a massive heart attack, also called sudden cardiac
arrest.
The project began with Miami's selection of Cardiac
Science last fall as
the city's exclusive provider of AEDs. City officials
stated that they plan to
deploy Powerheart AEDs in police and fire vehicles
as well as city facilities
and other public locations where large numbers of
people congregate.
"We are working very closely with city officials
in Miami to ensure their
PAD program is as successful as the San Diego Project
Heartbeat PAD program
where over 1,200 Powerheart AEDs have been deployed
since 2001 and dozens of
lives have been saved as a result," said Cardiac
Science Chairman and Chief
Executive Officer Raymond W. Cohen. "We consider
the partnership between
Cardiac Science and Miami to be an excellent example
of how cities can work
with private industry to improve safety and public
education. Everyone who
lives in Miami or visits the city could benefit directly
from the 'Team for
Life' project."
About Cardiac Science
Cardiac Science develops, manufactures and markets
a complete line of
Powerheart(R) brand, automatic public access defibrillators
(AEDs), and offers
comprehensive AED/CPR training and AED program management
services that
facilitate successful deployments. The company makes
the Powerheart(R)
CRM(R), the only FDA-cleared therapeutic patient monitor
that instantly and
automatically treats hospitalized cardiac patients
who suffer life-threatening
heart rhythms. Cardiac Science also manufactures its
AED products on a
private label basis for other leading medical companies
such as Nihon Kohden
(Japan), Quinton Cardiology Systems and GE Healthcare.
This press release includes forward-looking statements.
These statements
may be identified by the use of forward-looking terminology
such as
"anticipate," "believe," "continue,"
"could," "estimate," "expect,"
"intend,"
"may," "might," "plan,"
"potential," "predict," "should,"
or "will," or the
negative thereof or other variations thereon or comparable
terminology.
Cardiac Science has based these forward-looking statements
on the current
expectations, assumptions, estimates and projections.
While Cardiac Science
believes the City of Miami PAD project will lead to
future purchases of AEDs
and be a benefit to the city of Miami and it citizens,
these expectations,
assumptions, estimates and projections, while reasonable,
are forward-looking
statements and are only predictions and involve known
and unknown risks and
uncertainties, many of which are beyond our control.
Certain factors,
including those discussed in Cardiac Sciences' Annual
Report on Form 10-K for
the year ended December 31, 2004, under the heading
"Risk Factors," may cause
the actual results, performance or achievements to
differ materially from any
future results, performance or achievements expressed
or implied by these
forward-looking statements. Given these risks and
uncertainties, you are
cautioned not to place undue reliance on such forward-looking
statements. We
do not undertake any obligation to update any such
statements or to publicly
announce the results of any revisions to any such
statements to reflect future
events or developments. |
